Prostate-specific membrane antigen (PSMA) is a target for diagnostic positron emission tomography (PET)-tracers and radiopharmaceutical therapy (RPT), for example, [177Lu]Lu-PSMA-617, in prostate cancer. This autoradiography study investigates [177Lu]Lu-PSMA-617 intratumoral distribution over time, compared with PSMA expression, proliferation (Ki67), and [68Ga]Ga-PSMA-11, [18F]F-PSMA-1007, [18F]-fluorodeoxyglucose, and [18F]-fluorocholine distribution. Mice with LNCaP, 22Rv1, or PC-3 PIP xenografts got [177Lu]Lu-PSMA-617 i.v. Sacrificed 1 h p.i. if coinjected with diagnostic tracers, otherwise at 20 min, 1–2, 12, 24, 48, 72 h, or 2–3 weeks p.i. Cryosectioned tumors imaged by autoradiography, adjacent sections Ki67 or PSMA stained.
Results:
Heterogeneous distribution of [177Lu]Lu-PSMA-617 was seen 20 min p.i., with visible overlap between tumor cells, Ki67, PSMA, and radioactivity at 1–2 h p.i. Strongest Ki67-correlation at 48 h, which became negative at 72 h and beyond with some Ki67+/PSMA+ low radioactivity areas. Uptake in necrotic tissue was only observed at 2–3 weeks p.i. PSMA-targeted tracers distributed identically to [177Lu]Lu-PSMA-617 whereas other tracers only had some overlap.
Conclusion:
Regrowth of the tumor post-[177Lu]Lu-PSMA-617 administration creates Ki67+/PSMA+ areas that have no radioactivity uptake and need additional therapy fractions. The identical intratumoral distribution of [177Lu]Lu-PSMA-617 and PSMA-targeted PET-tracers indicate that these will reveal the areas inside the tumor targeted by RPT at least at 1 h p.i.
Get full access to this article
View all access options for this article.
References
1.
JamesND, SpearsMR, ClarkeNW, et al.Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol, 2015; 67(6):1028–1038; doi: 10.1016/j.eururo.2014.09.032
2.
ShoreND, AntonarakisES, CooksonMS, et al.Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate, 2020; 80(6):527–544; doi: 10.1002/pros.23967
3.
DebnathS, ZhouN, McLaughlinM, et al.PSMA-targeting imaging and theranostic agents—Current status and future perspective. Int J Mol Sci, 2022; 23(3):1158; doi: 10.3390/ijms23031158
4.
KinoshitaY, KuratsukuriK, LandasS, et al.Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg, 2006; 30(4):628–636; doi: 10.1007/s00268-005-0544-5
5.
WrightGLJr, HaleyC, BeckettML, et al.Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol, 1995; 1(1):18–28; doi: 10.1016/1078-1439(95)00002-y
6.
SartorO, De BonoJ, ChiKN, et al.VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med, 2021; 385(12):1091–1103; doi: 10.1056/NEJMoa2107322
7.
FallahJ, AgrawalS, GittlemanH, et al.FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res, 2023; 29(9):1651–1657; doi: 10.1158/1078-0432.CCR-22-2875
8.
ChangC-H, WuH-C, TsaiJJ, et al.Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int, 2003; 70(4):311–315; doi: 10.1159/000070141
9.
JadvarH, DesaiB, JiL, et al.Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med, 2013; 54(8):1195–1201; doi: 10.2967/jnumed.112.114116
10.
JadvarH, VelezEM, DesaiB, et al.Prediction of time to hormonal treatment failure in metastatic castration-sensitive prostate cancer with 18F-FDG PET/CT. J Nucl Med, 2019; 60(11):1524–1530; doi: 10.2967/jnumed.118.223263
11.
PoulsenMH, PetersenH, Høilund‐CarlsenPF, et al.Spine metastases in prostate cancer: Comparison of technetium‐99m‐MDP whole‐body bone scintigraphy, [18 F] choline positron emission tomography (PET)/computed tomography (CT) and [18 F] NaF PET/CT. BJU Int, 2014; 114(6):818–823; doi: 10.1111/bju.12599
12.
KrauseB, SouvatzoglouM, TuncelM, et al.The detection rate of [11 C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging, 2008; 35(1):18–23; doi: 10.1007/s00259-007-0581-4
13.
WangX, WenQ, ZhangH, et al.Head-to-head comparison of 68Ga-PSMA-11 PET/CT and multiparametric MRI for pelvic lymph node staging prior to radical prostatectomy in patients with intermediate to high-risk prostate cancer: A meta-analysis. Front Oncol, 2021; 11:737989; doi: 10.3389/fonc.2021.737989
14.
HicksRM, SimkoJP, WestphalenAC, et al.Diagnostic accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology, 2018; 289(3):730–737; doi: 10.1148/radiol.2018180788
15.
GieselFL, KnorrK, SpohnF, et al.Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med, 2019; 60(3):362–368; doi: 10.2967/jnumed.118.212233
16.
GieselFL, HadaschikB, CardinaleJ, et al.F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging, 2017; 44(4):678–688; doi: 10.1007/s00259-016-3573-4
17.
GrünigH, MaurerA, ThaliY, et al.Focal unspecific bone uptake on [18 F]-PSMA-1007 PET: A multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging, 2021; 48(13):4483–4494; doi: 10.1007/s00259-021-05424-x
18.
SolonE, BalaniS, LeeF. Whole-body autoradiography in drug discovery. Curr Drug Metab, 2002; 3(5):451–462; doi: 10.2174/1389200023337207
19.
TronchinS, ForsterJC, HicksonK, et al.Dosimetry in targeted alpha therapy. A systematic review: Current findings and what is needed. Phys Med Biol, 2022; 67(9):09TR01; doi: 10.1088/1361-6560/ac5fe0
20.
ÖrbomA, ErikssonSE, ElgströmE, et al.The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model. J Nucl Med, 2013; 54(8):1404–1410; doi: 10.2967/jnumed.112.117028
21.
RuigrokEA, van VlietN, DalmSU, et al.Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging, 2021; 48(5):1339–1350; doi: 10.1007/s00259-020-05057-6
22.
HanX-D, LiuC, LiuF, et al.64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget, 2017; 8(43):74159–74169; doi: 10.1863/2/oncotarget.18276
23.
ZhangH, AbouD, LuP, et al.[18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response. Sci Rep, 2022; 12(1):13034; doi: 10.1038/s41598-022-17460-0
24.
KratochwilC, GieselFL, StefanovaM, et al.PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med, 2016; 57(8):1170–1176; doi: 10.2967/jnumed.115.171397
25.
GorgesTM, RiethdorfS, von AhsenO, et al.Heterogeneous PSMA expression on circulating tumor cells-a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget, 2016; 7(23):34930–34941; doi: 10.1863/2/oncotarget.9004
ÖrbomA, AhlstedtJ, SerénT, et al.Characterization of a double‐sided silicon strip detector autoradiography system. Med Phys, 2015; 42(2):575–584; doi: 10.1118/1.4905049
28.
FischerAH, JacobsonKA, RoseJ, et al.Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc, 2008; 2008(5):pdb.prot4986; doi: 10.1101/pdb.prot4986
29.
DerksYH, RijpkemaM, Amatdjais-GroenenHI, et al.Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer. Theranostics, 2021; 11(4):1527–1541; doi: 10.7150/thno.52166
30.
SchneiderCA, RasbandWS, EliceiriKW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 2012; 9(7):671–675; doi: 10.1038/nmeth.2089
31.
TuominenVJ, RuotoistenmäkiS, ViitanenA, et al.ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res, 2010; 12(4):R56; doi: 10.1186/bcr2615
32.
KristianssonA, CebergC, BjartellA, et al.Investigating Ras homolog gene family member C (RhoC) and Ki67 expression following external beam radiation therapy show increased RhoC expression in relapsing prostate cancer xenografts. Biochem Biophys Res Commun, 2024; 728:150324; doi: 10.1016/j.bbrc.2024.150324
33.
NguyenDP, XiongPL, LiuH, et al.Induction of PSMA and internalization of an anti-PSMA mAb in the vascular compartment. Mol Cancer Res, 2016; 14(11):1045–1053; doi: 10.1158/1541-7786.MCR-16-0193
34.
AbouzayedA, ZedanW, AltaiM, et al.Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu] Lu-PSMA-617 therapy in an animal model of prostate cancer. Am J Nucl Med Mol Imaging, 2023; 13(3):107–117.
35.
WangH, RemkeM, HornT, et al.Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer. EJNMMI Res, 2023; 13(1):99; doi: 10.1186/s13550-023-01044-8
36.
ZhangW, FanW, RachaganiS, et al.Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: Vascular perfusion, vasculature density, hypoxic burden and BB2r-targeting efficacy. Sci Rep, 2019; 9(1):11117; doi: 10.1038/s41598-019-47308-z
37.
FraumTJ, LudwigDR, KimEH, et al.Prostate cancer PET tracers: Essentials for the urologist. Can J Urol, 2018; 25(4):9371–9383.
38.
RaoDV, HowellRW. Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides. J Nucl Med, 1993; 34(10):1801–1810.
CurrentK, MeyerC, MagyarCE, et al.Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res, 2020; 26(12):2946–2955; doi: 10.1158/1078-0432.CCR-19-1485
41.
RoeskeJC, AydoganB, BardiesM, et al.Small-scale dosimetry: Challenges and future directions. Semin Nucl Med, 2008; 38(5):367–383; doi: 10.1053/j.semnuclmed.2008.05.003
42.
JacksonP, HofmanM, McIntoshL, et al.Radiation dosimetry in 177Lu-PSMA-617 therapy. Semin Nucl Med, 2022; 52(2):243–254; doi: 10.1053/j.semnuclmed.2021.11.003
43.
LassmannM, EberleinU. The relevance of dosimetry in precision medicine. J Nucl Med, 2018; 59(10):1494–1499; doi: 10.2967/jnumed.117.206649
MellhammarE, DahlbomM, Vilhelmsson-TimmermandO, et al.Tumor control probability and small-scale Monte Carlo dosimetry: Effects of heterogenous intratumoral activity distribution in radiopharmaceutical therapy. J Nucl Med, 2023; 64(10):1632–1637; doi: 10.2967/jnumed.123.265523
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
